[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:myasthenia-gravis:autoantibody":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Myasthenia Gravis","Autoantibody",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07673744","A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:13.549512Z","2026-07-05T03:45:20.432625Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases",[20],"Phase 1","2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.963761Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT00704626","Serum Auto-Antibodies in Neurological Diseases",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:25.538428Z","2026-06-16T05:54:07.944323Z"]